STOCK TITAN

Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Sight Sciences, Inc. (Nasdaq: SGHT), an innovative eyecare technology company, will report its financial results for Q1 2023 after market close on May 4, 2023. Management will host a conference call at 1:30 PM PT to discuss these results. Investors can access the live and archived webcast through the company’s website. Sight Sciences develops advanced solutions, including the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease, targeting prevalent eye diseases through non-invasive methods. These innovations aim to improve patient care and replace outdated treatments, positioning the company strongly in the eyecare market.

Positive
  • Upcoming financial results announcement for Q1 2023 may indicate growth potential.
  • Innovative products like OMNI® and TearCare® demonstrated commitment to addressing significant eye health issues.
Negative
  • None.

MENLO PARK, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 4, 2023. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

For more information, visit www.sightsciences.com.

OMNI and TearCare are registered trademarks of Sight Sciences. SION is a trademark of Sight Sciences.   © 2023 Sight Sciences. All rights reserved.

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com

 


FAQ

What are the financial results announcement dates for Sight Sciences (SGHT) in 2023?

Sight Sciences will announce its Q1 2023 financial results on May 4, 2023.

When is the conference call for Sight Sciences' Q1 2023 results?

The conference call for Q1 2023 results will be held at 1:30 PM PT on May 4, 2023.

How can I access the Sight Sciences (SGHT) earnings call?

Investors can access the earnings call via a live and archived webcast on the Sight Sciences website.

What products does Sight Sciences (SGHT) offer?

Sight Sciences offers the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease.

Sight Sciences, Inc.

NASDAQ:SGHT

SGHT Rankings

SGHT Latest News

SGHT Stock Data

204.36M
40.24M
19.9%
51.1%
2.23%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MENLO PARK